RU2002112248A - Лечение вирусных инфекций с использованием левовирина - Google Patents
Лечение вирусных инфекций с использованием левовиринаInfo
- Publication number
- RU2002112248A RU2002112248A RU2002112248/14A RU2002112248A RU2002112248A RU 2002112248 A RU2002112248 A RU 2002112248A RU 2002112248/14 A RU2002112248/14 A RU 2002112248/14A RU 2002112248 A RU2002112248 A RU 2002112248A RU 2002112248 A RU2002112248 A RU 2002112248A
- Authority
- RU
- Russia
- Prior art keywords
- response
- administration
- stage
- amplification
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Claims (13)
1. Способ лечения вирусной инфекции у пациента, при котором вводят соединение, соответствующее структуре 1,
где структура 1 представляет собой
2. Способ по п.1, где вирусная инфекция выбрана из группы, состоящей из инфекции вируса иммунодефицита человека (HIV), инфекции вируса гепатита С (HCV) и инфекции вируса гепатита В (HBV).
3. Способ по п.1, где стадия введения усиливает у пациента Th1-ответ по сравнению с Th2-ответом.
4. Способ по п.3, где усиливается Th1-ответ.
5. Способ по п.4, где усиление Th1-ответа включает в себя среднее пиковое возрастание по сравнению с активированным контрольным уровнем интерлейкина-2 (ИЛ-2), составляющее по меньшей мере 70 мас.%.
6. Способ по п.4, где усиление Th1-ответа включает в себя среднее пиковое возрастание по сравнению с активированным контрольным уровнем гамма-интерферона (ИФН-γ), составляющее по меньшей мере 20 мас.%.
7. Способ по п.4, где усиление Th1-ответа включает в себя среднее пиковое возрастание по сравнению с активированным контрольным уровнем фактора некроза опухоли α (ФНО-α), составляющее по меньшей мере 50 мас.%.
8. Способ по п.4, где усиление Th1-ответа включает в себя среднее пиковое возрастание по сравнению с активированным контрольным уровнем ИЛ-2, ИФН-γ и ФНО-α, составляющее 42, 125 и 72 мас.%, соответственно.
9. Способ по п.1, где стадия введения включает в себя введение in vivo.
10. Способ по п.1, где стадия введения включает в себя пероральное введение.
11. Способ по п.1, где стадия введения включает в себя инъекцию.
12. Способ по п.1, где стадия введения включает в себя введение соединения в дозе от 0,1 мг на кг массы тела пациента до 1,0 мг на кг массы тела пациента.
13. Модулятор иммунного ответа, соответствующий структуре 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/471,513 US6518253B1 (en) | 1999-11-19 | 1999-12-23 | Treatment of viral infections using the L-isomer of ribavirin |
| US09/471,513 | 1999-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002112248A true RU2002112248A (ru) | 2004-01-20 |
Family
ID=23871906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002112248/14A RU2002112248A (ru) | 1999-12-23 | 2000-12-15 | Лечение вирусных инфекций с использованием левовирина |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6518253B1 (ru) |
| EP (1) | EP1246832A1 (ru) |
| JP (1) | JP2003518134A (ru) |
| KR (1) | KR20030016213A (ru) |
| CN (1) | CN1409721A (ru) |
| AU (1) | AU2281601A (ru) |
| BR (1) | BR0016163A (ru) |
| CA (1) | CA2384110A1 (ru) |
| CZ (1) | CZ2002968A3 (ru) |
| HK (1) | HK1050011A1 (ru) |
| HR (1) | HRP20020486A2 (ru) |
| HU (1) | HUP0400500A2 (ru) |
| IL (1) | IL148510A0 (ru) |
| MX (1) | MXPA02006259A (ru) |
| NO (1) | NO20022816D0 (ru) |
| PL (1) | PL356640A1 (ru) |
| RU (1) | RU2002112248A (ru) |
| SI (1) | SI21042A (ru) |
| SK (1) | SK6252002A3 (ru) |
| WO (1) | WO2001046212A1 (ru) |
| YU (1) | YU47702A (ru) |
| ZA (1) | ZA200202739B (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638496B2 (en) | 2000-02-15 | 2009-12-29 | Valeant Pharmaceuticals North America | Nucleoside analogs with carboxamidine modified monocyclic base |
| KR101005299B1 (ko) | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| CA2493454A1 (en) * | 2002-08-12 | 2004-03-04 | F. Hoffmann-La Roche Ag | Process for producing a ribofuranose |
| CN1742018A (zh) * | 2002-12-10 | 2006-03-01 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的核苷衍生物 |
| AU2003302275A1 (en) * | 2003-01-07 | 2004-08-10 | Kemin Pharma Europe Bvba | Bicyclic carbohydrate compounds useful in the treatment of infections caused by flaviviridae sp., such as hepatitis c and bovine viral diarrhea viruses |
| US20050009848A1 (en) * | 2003-07-10 | 2005-01-13 | Icn Pharmaceuticals Switzerland Ltd. | Use of antivirals against inflammatory bowel diseases |
| US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
| US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
| US20140010783A1 (en) * | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
| AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| CN106687118A (zh) | 2014-07-02 | 2017-05-17 | 配体药物公司 | 前药化合物及其用途 |
| EP3737676B1 (en) | 2018-01-09 | 2024-03-06 | Ligand Pharmaceuticals, Inc. | Acetal compounds and therapeutic uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US6150337A (en) * | 1996-01-23 | 2000-11-21 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes |
| JP2002503212A (ja) * | 1996-10-16 | 2002-01-29 | アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド | 単環式ヌクレオシド、その類似体および使用 |
-
1999
- 1999-12-23 US US09/471,513 patent/US6518253B1/en not_active Expired - Lifetime
-
2000
- 2000-12-15 KR KR1020027008071A patent/KR20030016213A/ko not_active Application Discontinuation
- 2000-12-15 SK SK625-2002A patent/SK6252002A3/sk not_active Application Discontinuation
- 2000-12-15 US US10/168,941 patent/US20030092644A1/en not_active Abandoned
- 2000-12-15 CN CN00817021A patent/CN1409721A/zh active Pending
- 2000-12-15 MX MXPA02006259A patent/MXPA02006259A/es unknown
- 2000-12-15 JP JP2001547121A patent/JP2003518134A/ja active Pending
- 2000-12-15 BR BR0016163-2A patent/BR0016163A/pt not_active IP Right Cessation
- 2000-12-15 WO PCT/US2000/034610 patent/WO2001046212A1/en not_active Application Discontinuation
- 2000-12-15 YU YU47702A patent/YU47702A/sh unknown
- 2000-12-15 CA CA002384110A patent/CA2384110A1/en not_active Abandoned
- 2000-12-15 PL PL00356640A patent/PL356640A1/xx not_active Application Discontinuation
- 2000-12-15 SI SI200020046A patent/SI21042A/sl not_active IP Right Cessation
- 2000-12-15 HU HU0400500A patent/HUP0400500A2/hu unknown
- 2000-12-15 AU AU22816/01A patent/AU2281601A/en not_active Abandoned
- 2000-12-15 CZ CZ2002968A patent/CZ2002968A3/cs unknown
- 2000-12-15 EP EP00986610A patent/EP1246832A1/en not_active Withdrawn
- 2000-12-15 RU RU2002112248/14A patent/RU2002112248A/ru unknown
- 2000-12-15 IL IL14851000A patent/IL148510A0/xx unknown
-
2002
- 2002-04-08 ZA ZA200202739A patent/ZA200202739B/en unknown
- 2002-06-03 HR HR20020486A patent/HRP20020486A2/hr not_active Application Discontinuation
- 2002-06-13 NO NO20022816A patent/NO20022816D0/no not_active Application Discontinuation
-
2003
- 2003-03-28 HK HK03102256.2A patent/HK1050011A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200202739B (en) | 2003-09-23 |
| NO20022816L (no) | 2002-06-13 |
| KR20030016213A (ko) | 2003-02-26 |
| YU47702A (sh) | 2005-11-28 |
| HRP20020486A2 (en) | 2004-08-31 |
| US6518253B1 (en) | 2003-02-11 |
| IL148510A0 (en) | 2002-09-12 |
| CN1409721A (zh) | 2003-04-09 |
| CA2384110A1 (en) | 2001-06-28 |
| PL356640A1 (en) | 2004-06-28 |
| CZ2002968A3 (cs) | 2003-10-15 |
| MXPA02006259A (es) | 2003-01-28 |
| HK1050011A1 (zh) | 2003-06-06 |
| AU2281601A (en) | 2001-07-03 |
| JP2003518134A (ja) | 2003-06-03 |
| WO2001046212A1 (en) | 2001-06-28 |
| NO20022816D0 (no) | 2002-06-13 |
| SI21042A (sl) | 2003-04-30 |
| SK6252002A3 (en) | 2003-02-04 |
| HUP0400500A2 (hu) | 2004-07-28 |
| EP1246832A1 (en) | 2002-10-09 |
| BR0016163A (pt) | 2002-08-13 |
| US20030092644A1 (en) | 2003-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002120922A (ru) | Нуклеозидные аналоги с карбоксамидин-модифицированным моноциклическим основанием | |
| JP2004509061A5 (ru) | ||
| JP2003526662A5 (ru) | ||
| RU2002112248A (ru) | Лечение вирусных инфекций с использованием левовирина | |
| NZ500763A (en) | Use of PEG 12000-IFN alpha in treating viral infection | |
| RU98115594A (ru) | Модуляция экспрессии тн1/тн2 цитокинов рибавирином и аналогами рибавирина в активированных т-лимфоцитах | |
| WO2001068078A3 (en) | Immunostimulatory polynucleotide sequences for use in suppressing hepatitis virus infection | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| Van Thiel et al. | Combination treatment of advanced HCV associated liver disease with interferon and G-CSF | |
| PE20001386A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa | |
| WO2000018417A3 (en) | Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine | |
| MY139068A (en) | Treatment of hepatitis c in the asian population with subcutaneous interferon-beta | |
| RASMUSSEN et al. | Effect of interferon therapy on circulating lymphocytes in humans | |
| Krastev et al. | The prevention of an expected hepatic flare in HBe negative patients after lamivudine discontinuation | |
| KR20080027944A (ko) | ＨＢＶ 치료용 ＰＥＧ-ＩＦＮ α 및 리바비린 | |
| RU2001125429A (ru) | Лечение хронических вирусных инфекций m. vaccae | |
| Trépo et al. | Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection | |
| Palca | International doubts about a Kenyan cure | |
| JP2018131439A5 (ru) | ||
| Sulkowski | Hepatitis C virus and HIV co-infection: a sleeping giant wakes | |
| James | Ribavirin approved for hepatitis C combination treatment | |
| Lewert | Psychosocial needs of HIV-infected children and their families. | |
| EP0362755A3 (en) | Human cytotoxic t-cell clone and antibody thereto | |
| Kotsur et al. | ESTIMATION OF ANTIVIRAL THERAPY EFFICIENCY IN PATIENTS, WITH CHRONIC HEPATITIS C AND HIV | |
| RU2022130042A (ru) | Способ повышения устойчивости организма к особо опасным инфекционным заболеваниям бактериальной и вирусной природы |